Vitiligo patients from India (Mumbai) show differences in clinical, demographic and autoantibody profiles compared to patients in western countries

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 3, 2013, Pages 279-286

  Pradhan, V ^a   Patwardhan, M ^a   Thakkar, V ^a   Kharkar, V ^a   Khopkar, U ^a   Ghosh, K ^a   Weetman, A P ^b   Gawkrodger, D J ^c   Kemp, E H ^b  

^a KEM HOSPITAL   (India)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; MONOPHENOL MONOOXYGENASE; THYROGLOBULIN; THYROID PEROXIDASE; TYROSINE 3 MONOOXYGENASE;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNE DISEASE; DEMOGRAPHY; DISEASE DURATION; FAMILY HISTORY; FEMALE; HUMAN; INDIA; KERATINOCYTE; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; PREVALENCE; PRIORITY JOURNAL; SEROLOGY; VITILIGO;

ADULT; AUTOANTIBODIES; CHILD; DEMOGRAPHY; DEVELOPED COUNTRIES; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; VITILIGO;

EID: 84874106048     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04367.x     Document Type: Article

References (50)

1. Taieb A, Picardo M, Vitiligo European Task Force (VETF) Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007; 20: 27-35.
2. Sun X, Xu A, Wei X, et al. Study on genetic epidemiology in 815 patients with vitiligo in Zhejiang area. J Eur Acad Dermatol Venereol 2005; 26: 911-914.
3. Howitz J, Brodthagen H, Schwartz M, Tomsen K,. Prevalence of vitiligo: epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol 1977; 113: 47-52.
4. Sehgal VN, Srivastava G,. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol 2007; 73: 149-156.
5. Herane MI,. Vitiligo and leukoderma in children. Clin Dermatol 2003; 21: 283-295.
6. Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their relatives. Pigment Cell Res 2003; 16: 208-214.
7. Le Poole IC, Luiten RM,. Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun 2008; 10: 227-243.
8. Austin LM, Boissy RE,. Mammalian tyrosinase-related protein-1 is recognised by autoantibodies from vitiliginous Smyth chickens. Am J Pathol 1995; 146: 1529-1541.
9. Gawkrodger DJ, Ormerod AD, Shaw L, et al. Vitiligo: concise evidence based guidelines on diagnosis and management. Postgrad Med J 2010; 86: 466-471.
10. Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med 2010; 123: 183.
11. Spritz RA,. Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease. Thyroid 2010; 20: 745-754.
12. Van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009; 129: 2220-2232.
13. Klarquist J, Denman CJ, Hernandez C, et al. Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res 2010; 23: 276-286.
14. Van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C., et al. Local immune response in skin of generalised vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 2000; 80: 1299-1309.
15. Song YH, Connor E, Li Y, et al. The role of tyrosinase in autoimmune vitiligo. Lancet 1994; 344: 1049-1052.
16. Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP,. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol 1997; 109: 495-500.
17. Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP,. Autoantibodies to human melanocyte-specific protein Pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Clin Exp Immunol 1998; 114: 333-338.
18. Kemp EH, Waterman EA, Hawes BE, et al. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 2002; 109: 923-930.
19. Kemp EH, Emhemad S, Akhtar S, et al. Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo. Exp Dermatol 2011; 20: 35-40.
20. Hann SK, Im S, Kim HI, et al. Increased incidence of antismooth muscle antibody in Korean vitiligo patients. J Dermatol 1993; 20: 679-683.
21. Betterle C, Caretto A, De Zio A, et al. Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only autoantibodies) in patients with vitiligo. Dermatologica 1985; 171: 419-423.
22. Zettinig G, Tanew A, Fischer G, et al. Autoimmune diseases in vitiligo: do anti-nuclear antibodies decrease thyroid volume? Clin Exp Immunol 2003; 131: 347-354.
23. Ingordo V, Gentile C, Iannazzone SS, et al. Vitiligo and autoimmunity: an epidemiological study in a representative sample of young Italian males. J Eur Acad Dermatol Venereol 2010; 25: 105-109.
24. Yu HS, Kao CH, Yu CL,. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. J Invest Dermatol 1993; 100: 823-828.
25. Dell'Anna ML, Picardo M,. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res 2006; 19: 406-411.
26. Kroll TM, Bommiasamy H, Boissy RE, et al. 4-tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol 2005; 124: 798-806.
27. Das SK, Majumder PP, Chakraborty R, et al. Studies on vitiligo. I. Epidemiological profile in Calcutta, India. Genet Epidemiol 1984; 2: 71-78.
28. Handa S, Kaur I,. Vitiligo: clinical findings in 1436 patients. J Dermatol 1999; 26: 653-657.
29. Handa S, Dogra S,. Epidemiology of childhood vitiligo: a study of 625 patients from north India. Pediatr Dermatol 2003; 20: 207-210.
30. Dogra S, Parsad D, Handa S, Kanwar AJ,. Late onset vitiligo: a study of 182 patients. Int J Dermatol 2004; 44: 193-196.
31. Shajil EM, Agrawal D, Vagadia K, et al. Clinical profiles in Vadodara, Gujarat. Ind J Dermatol 2006; 51: 100-104.
32. Poojary SA,. Vitiligo and associated autoimmune disorders: a retrospective hospital-based study in Mumbai, India. Allergol Immunopathol 2011; 39: 356-361.
33. Kemp EH, Waterman EA, Gawkrodger DJ, et al. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol 1998; 139: 798-805.
34. Waterman EA, Kemp EH, Gawkrodger DJ, et al. Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1. Clin Exp Immunol 2002; 129: 527-532.
35. Liu JB, Li M, Yang S, et al. Clinical profiles of vitiligo in China: an analysis of 3742 patients. Clin Dermatol 2007; 30: 327-331.
36. Akrem J, Baroudi A, Aichi T, et al. Profile of vitiligo in the south of Tunisia. Int J Dermatol 2008; 47: 670-674.
37. Garsaud AM, Garsaud P, Cales-Quist D,. Epidemiology of vitiligo in the French West Indies (Isle Martinique). Int J Dermatol 2000; 39: 18-20.
38. Berti S, Bellandi S, Bertelli A, et al. Vitiligo in an Italian outpatient center: a clinical and serologic study of 204 patients in Tuscany. Am J Clin Dermatol 2011; 12: 43-49.
39. Shah H, Mehta A, Astik B,. Clinical and sociodemographic study of vitiligo. Indian J Dermatol Venereol Leprol 2008; 74: 701-703.
40. Gopal KVT, Rao GRR, Kumar YHK, et al. Vitiligo: a part of a systemic autoimmune process. Indian J Dermatol Venereol Leprol 2007; 73: 162-165.
41. Mason CP, Gawkrodger DJ,. Vitiligo presentation in adults. Clin Exp Dermatol 2005; 30: 344-345.
42. Dave S, D'Souza M, Thappa DM, et al. High frequency of thyroid dysfunction in Indian patients with vitiligo. Indian J Dermatol 2003; 48: 68-72.
43. Baharav E, Merimski O, Shoenfeld Y, et al. Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 1996; 105: 84-88.
44. Okamoto T, Irie RF, Fujii S, et al. Anti-tyrosinase-related protein-2 immune response in vitiligo and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 1998; 111: 1034-1039.
45. Li Q, Lv Y, Li C, et al. Vitiligo autoantigen VIT75 is identified as lamin A in vitiligo by serological proteome analysis based on mass spectrometry. J Invest Dermatol 2010; 131: 727-734.
46. Harning R, Cui J, Bystryn J-C,. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991; 97: 1078-1080.
47. Ezzedine K, Diallo A, Leaute-Labreze D, et al. Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patients. Br J Dermatol 2011; 165: 44-49.
48. Mandry RC, Ortiz LJ, Lugo-Somolinos A, Sanchez JL,. Organ-specific autoantibodies in vitiligo patients and their relatives. Int J Dermatol 1996; 35: 18-21.
49. Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008; 159: 1051-1076.
50. Sehgal VN,. Vitiligo and alopecia areata associated with subclinical/clinical hypothyroidism. SkinMed 2011; 9: 192-194.